Physician profile
Maurie Markman
NPI 1669564696
$203,917.40
in general payments reported to CMS, 2019-2025
9 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what 76% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84K · 2020: $36K · 2021: $26K · 2022: $19K · 2023: $3,626 · 2024: $33K · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,560 · Travel and Lodging: $1,879 · Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,815.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,560.00 |
| Travel and Lodging | $1,878.53 |
| Food and Beverage | $287.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $71,130.06 | 2019-2024 | Lynparza |
| Glaxosmithkline, LLC. | $54,108.32 | 2020-2025 | Zejula |
| Genentech USA, INC. | $31,496.08 | 2019 | |
| Clovis Oncology, INC. | $19,721.05 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $17,622.59 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $6,853.51 | 2024 | Precisetumor |
| Amgen INC. | $2,596.00 | 2020 | |
| La Jolla Pharmaceutical Company | $262.50 | 2020 | |
| Novartis Pharmaceuticals Corporation | $127.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurie Markman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.